Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x100px

Document › Details

OSE Immunotherapeutics S.A.. (9/7/17). "Press Release: OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of its Product Portfolio". Nantes.

	Organisation	OSE Immunotherapeutics S.A.
	Today	OSE Pharma S.A.
	Group	OSE Immunotherapeutics (Group)
	Organisation 2	Janssen Biotech Inc. (JBI)
	Group	Johnson & Johnson (JnJ) (Group)
	Product	Tedopi® cancer immunotherapy
	Product 2	FR104 MAb fragment (Effimmune)
	Index term	Servier–OSE Immunotherapeutics: therapeutic antibody, 201612– license option ww excl up to €272m for Effi-7 immunomodulatory antibody to Servier
	Person	Costantini, Dominique (OSE Pharma 201504 CEO + Co-founder + former CEO + Co-founder of BioAlliance Pharma in 1997)
	Person 2	de Weese, David (Paul Capital 201504 Director + Board Member of OSE Pharma)

Original document
accessed by [iito] on 2017-09-15

Record changed: 2023-06-05

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for OSE Immunotherapeutics (Group)

[1] iOmx Therapeutics AG. (9/5/23). "Press Release: iOmx Therapeutics Appoints Dr. Nils Peter Debus as Chief Business Officer". Martinsried....
[2] OSE Immunotherapeutics S.A.. (10/7/22). "Press Release: OSE Immunotherapeutics Appoints Nicolas Poirier as Chief Executive Officer". Nantes....
[3] OSE Immunotherapeutics S.A.. (2/12/20). "Press Release: OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico". Nantes....
[4] OSE Immunotherapeutics S.A.. (2/7/19). "Press Release: OSE Immunotherapeutics and Servier Announce First Option within Global License Agreement Exercised for further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases"....
[5] Boehringer Ingelheim. (4/4/18). "Press Release: Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors". Ingelheim & Nantes....
[6] OSE Immunotherapeutics S.A.. (8/31/17). "Press Release: OSE Immunotherapeutics Announces Presentation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City, September 10-12, 2017". Nantes....
[7] OSE Immunotherapeutics S.A.. (7/19/17). "Press Release: OSE Immunotherapeutics Receives €9.2 Million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)". Nantes....
[8] Selexis S.A.. (5/23/17). "Press Release: Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist". Geneva & Nantes....
[9] OSE Immunotherapeutics S.A.. (2/7/17). "Press Release: OSE Immunotherapeutics to Present Corporate Overview at Upcoming BIO CEO & Investor Conference New York February 13-14, 2017". Nantes....
[10] McDermott Will & Emery. (1/6/17). "Press Release: McDermott Will & Emery Advised Servier in Its License Option Agreement with OSE Immunotherapeutics". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]